The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology
Open accessAbstract
Background: Exogenous replacement of erythropoietin (EPO) by recombinant human EPO has been considered a standard of care for the treatment of anemia in patients with chronic kidney disease for more than 20 years. Genetically engineered biologic proteins derived from human, animal, or microorganism sources are a major area of growth in modern medical care, accounting for one-third of new drug approvals in the past decade. Despite benefit to patients, the use of biologics comes at a significant cost, representing one of the fastest growing segments of strained healthcare budgets around the world. Summary: Biosimilars, or biologic drugs that are designed to be highly similar to approved reference biologic drugs, have been available in Europe for more than 10 years with no unusual or unexpected effects compared to their reference biologics whose patents have expired. Given the success of the biosimilar approval pathway pioneered in Europe, it has served as a global reference for other regulatory authorities to establish and implement biosimilar licensure frameworks, including the United States (US), the largest pharmaceutical market in the world. Given 10 of the top 25 drugs sold in 2014 were biologics, and considering the rising costs of healthcare, biosimilars have the potential to become a significant part of the US market. Key Messages: For the nephrology community, the recent patent expiries for epoetin alfa (Epogen®, Amgen and Procrit®, Johnson & Johnson) have created the opportunity to develop biosimilar EPOs. And while no biosimilar in this therapeutic class is approved in the US, there are proposed biosimilars in development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762 · cited 2×
“[17] The decision was based on key data obtained from the Normal Hematocrit Cardiac Trial (NHCT),[25] the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) study, [15] and the Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin Beta (CREATE) study.[16] Briefly, the results of NHCT p…”
Andrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930
Cloning and expression of the human erythropoietin gene.
Lin, F. K., Suggs, S., Lin, C. H., Browne, J. K., Smalling, R., Egrie, J. C., Chen, K. K., Fox, G. M., Martin, F., & Stabinsky, Z. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.22.7580 · Cited by 1,134
Purification of human erythropoietin.
Miyake, T., Kung, C. K., & Goldwasser, E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)63387-9 · Cited by 886
Jones, M., Ibels, L., Schenkel, B., & Zagari, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 665
Pure Red-Cell Aplasia and Epoetin Therapy
Bennett, C. L., Luminari, S., Nissenson, A. R., Tallman, M. S., Klinge, S. A., McWilliams, N., McKoy, J. M., Kim, B., Lyons, E. A., Trifilio, S. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040528 · Cited by 437
Cited by
Effects of protein aggregates: An immunologic perspective
Rosenberg, A. S. (2006) · The AAPS Journal · doi:10.1208/aapsj080359 · Cited by 1,355
Cloning and expression of the human erythropoietin gene.
Lin, F. K., Suggs, S., Lin, C. H., Browne, J. K., Smalling, R., Egrie, J. C., Chen, K. K., Fox, G. M., Martin, F., & Stabinsky, Z. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.22.7580 · Cited by 1,134
Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.13.5680 · Cited by 990
Davenport, A. P., Hyndman, K. A., Dhaun, N., Southan, C., Kohan, D. E., Pollock, J. S., Pollock, D. M., Webb, D. J., & Maguire, J. J. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011833 · Cited by 772
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Matsushita, K., Ballew, S. H., Wang, A. Y.-M., Kalyesubula, R., Schaeffner, E., & Agarwal, R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00616-6 · Cited by 670
Malcovati, L., Hellström-Lindberg, E., Bowen, D., Adès, L., Cermak, J., del Cañizo, C., Della Porta, M. G., Fenaux, P., Gattermann, N., Germing, U., et al. (2013) · Blood · doi:10.1182/blood-2013-03-492884 · Cited by 669
Jones, M., Ibels, L., Schenkel, B., & Zagari, M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00450.x · Cited by 665
The current and future landscape of dialysis
Himmelfarb, J., Vanholder, R., Mehrotra, R., & Tonelli, M. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0315-4 · Cited by 650
Mitochondrial dysfunction in diabetic kidney disease
Forbes, J. M., & Thorburn, D. R. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2018.9 · Cited by 634
Sieff, C. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112988 · Cited by 596
Stenvinkel, P., Carrero, J. J. A. A., Axelsson, J., Lindholm, B., Heimbu[Combining Diaeresis]rger, O., & Massy, Z. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03670807 · Cited by 561
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
A novel protective effect of erythropoietin in the infarcted heart
Parsa, C. J., Matsumoto, A., Kim, J., Riel, R. U., Pascal, L. S., Walton, G. B., Thompson, R. B., Petrofski, J. A., Annex, B. H., Stamler, J. S., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18200 · Cited by 548
Japanese clinical practice guideline for diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Diabetology International · doi:10.1007/s13340-020-00439-5 · Cited by 545
Biomarkers and surrogate endpoints in clinical trials
Fleming, T. R., & Powers, J. H. (2012) · Statistics in Medicine · doi:10.1002/sim.5403 · Cited by 544
Goodnough, L. T., Maniatis, A., Earnshaw, P., Benoni, G., Beris, P., Bisbe, E., Fergusson, D. A., Gombotz, H., Habler, O., Monk, T. G., et al. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aeq361 · Cited by 543
Metcalf, D. (2008) · Blood · doi:10.1182/blood-2007-03-079681 · Cited by 528
Development and characterization of novel erythropoiesis stimulating protein (NESP)
Egrie, J. C., & Browne, J. K. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1746 · Cited by 510
Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia
Kuhn, V., Diederich, L., Keller, T. C. S., Kramer, C. M., Lückstädt, W., Panknin, C., Suvorava, T., Isakson, B. E., Kelm, M., & Cortese-Krott, M. M. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6954 · Cited by 469
Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure
Xu, J., Li, G., Wang, P., Velazquez, H., Yao, X., Li, Y., Wu, Y., Peixoto, A., Crowley, S., & Desir, G. V. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524066 · Cited by 466
Overview of iron metabolism in health and disease
Dev, S., & Babitt, J. L. (2017) · Hemodialysis International · doi:10.1111/hdi.12542 · Cited by 462
Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney.
Lacombe, C., Da Silva, J. L., Bruneval, P., Fournier, J. G., Wendling, F., Casadevall, N., Camilleri, J. P., Bariety, J., Varet, B., & Tambourin, P. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113363 · Cited by 440
Guidelines for the management of chronic kidney disease
Levin, A., Hemmelgarn, B., Culleton, B., Tobe, S., McFarlane, P., Ruzicka, M., Burns, K., Manns, B., White, C., Madore, F., et al. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080351 · Cited by 420
Effects of graded doses of testosterone on erythropoiesis in healthy young and older men
Coviello, A. D., Kaplan, B., Lakshman, K. M., Chen, T., Singh, A. B., & Bhasin, S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1692 · Cited by 404
Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
Portolés, J., Martín, L., Broseta, J. J., & Cases, A. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.642296 · Cited by 369
Zoccali, C., Mallamaci, F., Adamczak, M., de Oliveira, R. B., Massy, Z. A., Sarafidis, P., Agarwal, R., Mark, P. B., Kotanko, P., Ferro, C. J., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad083 · Cited by 363
Japanese Clinical Practice Guideline for Diabetes 2019
Araki, E., Goto, A., Kondo, T., Noda, M., Noto, H., Origasa, H., Osawa, H., Taguchi, A., Tanizawa, Y., Tobe, K., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13306 · Cited by 341
Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment
Batchelor, E. K., Kapitsinou, P., Pergola, P. E., Kovesdy, C. P., & Jalal, D. I. (2020) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019020213 · Cited by 334
Anaemia in kidney disease: harnessing hypoxia responses for therapy
Koury, M. J., & Haase, V. H. (2015) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.82 · Cited by 313
Protein Design: From the Aspect of Water Solubility and Stability
Qing, R., Hao, S., Smorodina, E., Jin, D., Zalevsky, A., & Zhang, S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00757 · Cited by 312
Kandula, P., Dobre, M., Schold, J. D., Schreiber, M. J., Mehrotra, R., & Navaneethan, S. D. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03940510 · Cited by 302
Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease
Mikhail, A., Brown, C., Williams, J. A., Mathrani, V., Shrivastava, R., Evans, J., Isaac, H., & Bhandari, S. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0688-1 · Cited by 299
Chronic kidney disease in the elderly: evaluation and management
Mallappallil, M., Friedman, E. A., Delano, B. G., McFarlane, S. I., & Salifu, M. O. (2014) · Clinical Practice · doi:10.2217/cpr.14.46 · Cited by 298
Migliaccio, G., Migliaccio, A. R., Petti, S., Mavilio, F., Russo, G., Lazzaro, D., Testa, U., Marinucci, M., & Peschle, C. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112572 · Cited by 297
Besarab, A., Provenzano, R., Hertel, J., Zabaneh, R., Klaus, S. J., Lee, T., Leong, R., Hemmerich, S., Yu, K.-H. P., & Neff, T. B. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv302 · Cited by 286
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
Maxwell, P. H., & Eckardt, K.-U. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.193 · Cited by 283
Yoo, D. H., Prodanovic, N., Jaworski, J., Miranda, P., Ramiterre, E., Lanzon, A., Baranauskaite, A., Wiland, P., Abud-Mendoza, C., Oparanov, B., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208786 · Cited by 279
Takeuchi, M., Inoue, N., Strickland, T. W., Kubota, M., Wada, M., Shimizu, R., Hoshi, S., Kozutsumi, H., Takasaki, S., & Kobata, A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.20.7819 · Cited by 275
The multifaceted role of iron in renal health and disease
van Swelm, R. P. L., Wetzels, J. F. M., & Swinkels, D. W. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0197-5 · Cited by 275
Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action
Bello, A. K., Alrukhaimi, M., Ashuntantang, G. E., Basnet, S., Rotter, R. C., Douthat, W. G., Kazancioglu, R., Köttgen, A., Nangaku, M., Powe, N. R., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.007 · Cited by 270
Specific interaction of murine colony-stimulating factor with mononuclear phagocytic cells.
Guilbert, L. J., & Stanley, E. R. (1980) · The Journal of cell biology · doi:10.1083/jcb.85.1.153 · Cited by 264
Ferumoxytol for Treating Iron Deficiency Anemia in CKD
Spinowitz, B. S., Kausz, A. T., Baptista, J., Noble, S. D., Sothinathan, R., Bernardo, M. V., Brenner, L., & Pereira, B. J. G. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007101156 · Cited by 262
Alternatives to blood transfusion
Spahn, D. R., & Goodnough, L. T. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60808-9 · Cited by 261
Kadomatsu, K., Huang, R. P., Suganuma, T., Murata, F., & Muramatsu, T. (1990) · The Journal of cell biology · doi:10.1083/jcb.110.3.607 · Cited by 256
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
Aggregation of Protein Therapeutics Enhances Their Immunogenicity: Causes and Mitigation Strategies
Lundahl, M. L. E., Fogli, S., Colavita, P. E., & Scanlan, E. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00067e · Cited by 212
Baker, R. J., Mark, P. B., Patel, R. K., Stevens, K. K., & Palmer, N. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0553-2 · Cited by 211
Wong, M. M. Y., Tu, C., Li, Y., Perlman, R. L., Pecoits-Filho, R., Lopes, A. A., Narita, I., Reichel, H., Port, F. K., Sukul, N., et al. (2020) · Clinical Kidney Journal · doi:10.1093/ckj/sfz091 · Cited by 140
Development of spirulina for the manufacture and oral delivery of protein therapeutics
Jester, B. W., Zhao, H., Gewe, M., Adame, T., Perruzza, L., Bolick, D. T., Agosti, J., Khuong, N., Kuestner, R., Gamble, C., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01249-7 · Cited by 130
Coleman, T. R., Westenfelder, C., Tögel, F. E., Yang, Y., Hu, Z., Swenson, L., Leuvenink, H. G. D., Ploeg, R. J., d’Uscio, L. V., Katusic, Z. S., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601377103 · Cited by 127
Aggregation risk prediction for antibodies and its application to biotherapeutic development
Obrezanova, O., Arnell, A., de la Cuesta, R. G., Berthelot, M. E., Gallagher, T. R., Zurdo, J., & Stallwood, Y. (2015) · mAbs · doi:10.1080/19420862.2015.1007828 · Cited by 107
Perfluoroalkyl substances and kidney function in chronic kidney disease, anemia, and diabetes
Conway, B., Badders, A., Costacou, T., Arthur, J., & Innes, K. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s173809 · Cited by 80
Iron sucrose augments homocysteine-induced endothelial dysfunction in normal subjects
Zheng, H., Huang, X., Zhang, Q., & Katz, S. D. (2006) · Kidney International · doi:10.1038/sj.ki.5000046 · Cited by 44
Iron metabolism in critically ill patients developing anemia of inflammation: a case control study
Boshuizen, M., Binnekade, J. M., Nota, B., van de Groep, K., Cremer, O. L., Tuinman, P. R., Horn, J., Schultz, M. J., van Bruggen, R., Juffermans, N. P., et al. (2018) · Annals of Intensive Care · doi:10.1186/s13613-018-0407-5 · Cited by 39
Harlow, C. E., Gandawijaya, J., Bamford, R. A., Martin, E.-R., Wood, A. R., van der Most, P. J., Tanaka, T., Leonard, H. L., Etheridge, A. S., Innocenti, F., et al. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.08.004 · Cited by 13
Metadata
- Authors
- Kalantar-Zadeh, K.
- Venue
- American Journal of Nephrology
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 45
- Issue
- 3
- Pages
- 235-247
- ISSN
- 0250-8095 (ISSN-L)
- 1421-9670
- OpenAlex
- W2584947097
- Cited by
- 1,148
- References
- 21
- FWCI
- 34.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.